SCHEMBL31450141

SCHEMBL31450141

O=S(=O)(Cl)c1ccc(Cl)cc1Br

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.54
HTT P42858 2/20 0.54
TRPV4 Q9HBA0 2/20 0.53
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49
FLT1 P17948 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
CCR2 P41597 2/20 0.38
MAPK1 P28482 2/20 0.38
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
S100A4 P26447 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4142707 1.00 TSHR (0.54) TSHRHTTTRPV4LMNAHPGD
SCHEMBL28218707 0.83 TSHR (0.54) TSHRHTTTRPV4LMNAHPGD
SCHEMBL11653313 0.81 TSHR (0.53) TSHRHTTTRPV4LMNAHPGD
SCHEMBL31470482 0.80 HSP90AA1 (0.43) TSHRHTTTRPV4LMNAFLT1
SCHEMBL1814581 0.80 HSP90AA1 (0.43) TSHRHTTTRPV4LMNAFLT1
SCHEMBL444929 0.77 TRPV4 (0.57) TSHRTRPV4LMNAHPGDALDH1A1
SCHEMBL29519358 0.77 TRPV4 (0.57) TSHRTRPV4LMNAHPGDALDH1A1
SCHEMBL9997269 0.77 TRPV4 (0.35) TSHRHTTTRPV4LMNAHPGD
SCHEMBL10889465 0.77 TRPV4 (0.52) TSHRHTTTRPV4LMNAHPGD
SCHEMBL31645086 0.77 TRPV4 (0.39) TSHRHTTTRPV4LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224168-A1 ARYL SULFONE AND SULFANONE DERIVATIVES AS OREXIN RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-10-30 WO disclosed
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K VIVIDION THERAPEUTICS, INC. 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K KRAS, HRAS, NRAS TSHR 2577/4885HTT 1632/4885TRPV4 4643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.